Maybe just in time for it to be rendered ineffective against the next variant.Minor, but important news:
![]()
FDA Okays New Monoclonal Antibody That's Effective Against Omicron
The FDA has authorized Eli Lilly's COVID-19 antibody drug for people aged 12 and older at risk of severe illness.www.medscape.com
For those not following, the rise of the omicron variant rendered much of our national stock of monoclonal antibody cocktails useless . Of the three approved treatments, only sotrumivab showed efficacy against omicron, and unfortunately, our reserves and manufacturing capacity for this one were the lowest of the three. We've been playing catch-up ever since, and had to strictly ration what supplies of sotrumivab were available. I don't doubt that at least part of the reason why the death count has been so high with omicron was because people who previously could have been saved by a monoclonal antibody infusion now couldn't get one.
So, it's good to have bebtelovimab on board now, although like any new therapeutic, it will take awhile before they can ramp up production enough to start relieving some of the current supply shortages.
And what's the status of the oral treatments? Are those available to average schlubs yet?
Last edited by a moderator: